MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.

Clinical trial NCT07391839 · RECRUITING

Trial details

NCT number: NCT07391839
Sponsor: Suzhou Mednovo Yi Medical Technology Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatoma Unresectable Hepatocellular Carcinoma (HCC)

Start date: 2025-08-04
Primary completion: 2026-08-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.